Cresco Labs (CRLBF) Capital Leases (2023 - 2026)
Cresco Labs (CRLBF) posted Capital Leases of $17.6 million for Q1 2026, down 3.91% on a QoQ basis from $18.3 million in Q4 2025.
Cresco Labs (CRLBF) Capital Leases (2023 - 2026) Analysis & Trends
Cresco Labs' Capital Leases history runs 3 years deep, the most recent figure standing at $17.6 million for Q1 2026.
- Quarterly Capital Leases changed N/A year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.6 million (changed N/A YoY) and the FY2025 annual result came in at $18.3 million, changed N/A from the prior year.
- Capital Leases was $17.6 million for Q1 2026 at Cresco Labs, down from $18.3 million in the prior quarter.
- Across five years, Capital Leases topped out at $22.4 million in Q4 2023 and bottomed at $17.6 million in Q1 2026.
- A 3-year average of $19.4 million and a median of $18.3 million in 2025 frame the typical range for Capital Leases.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Cresco Labs | 245.85 Mn | 182.28 Mn | 75.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.56 Mn |
| Dec 31, 2025 | 18.27 Mn |
| Dec 31, 2023 | 22.38 Mn |